Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C ...

Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients ‌with type 2 diabetes not using ...

「Dexcom G7」は、糖尿病のある方の日常の血糖マネジメントを容易にする新しいリアルタイムCGMで、この度、革新的な前製品（Dexcom G6）を、より小さく、使いやすく、かつ手ごろな価格でリデザインした点が高く評価され、2024年度グッドデザイン賞を受賞し ...

A Dexcom continuous glucose monitor (CGM) helped adults with type 2 diabetes not using insulin improve blood sugar control in ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...

Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

Dexcom (Nadsaq:DXCM) has received FDA clearance for its Stelo over-the-counter (OTC) continuous glucose monitor (CGM) for ...